PillRx only · Tablet · Oral
Exemestane
Brands: Aromasin · Exemestane
5 ACTIVE SUPPLIERS — US
openFDA · updated weekly
US5 NDCs
5 active makers
5 active makers
UKComing
soon
soon
CAComing
soon
soon
AUComing
soon
soon
EUComing
soon
soon
US acquisition costNADAC · per unit
Average across 4 priced NDCs. A benchmark of pharmacy acquisition cost — not a retail quote.
$10.260
Latest avg · Jul 22, 2026
+1562%
Since Dec 17, 2025
5
Active US suppliers
40%
Top-2 supplier share*
Medicaid dispensing volumeSDUD · per quarter
Prescriptions dispensed under Medicaid (fee-for-service + managed care), summed nationally. The closest free proxy to sales volume — Medicaid only, not all-payer.
2.1K
Rx · 2026 Q1
87K
Units dispensed
-60%
Rx vs. year ago
5
Quarters · since 2025 Q1
Who makes it5 active · 0 exited
US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.
| Labeler | Type | Packages | Status |
|---|---|---|---|
| Upsher-Smith Laboratories, LLC | unknown | 1 | SUPPLYING |
| Pharmacia & Upjohn Company LLC | unknown | 1 | SUPPLYING |
| Zydus Lifesciences Limited | unknown | 1 | SUPPLYING |
| Zydus Pharmaceuticals USA Inc. | unknown | 1 | SUPPLYING |
| Cipla USA Inc. | unknown | 1 | SUPPLYING |
Regulatory & supply events
No recalls, shortages, or registration changes on record for this drug concept.